Compare Gilead Sciences, Inc. (GILD) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Southern Copper Corp — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Southern Copper Corp trades at $204 (market cap $167.74B). The key difference: Gilead Sciences, Inc. and Southern Copper Corp are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Southern Copper Corp for 61 Days on average.
| GILD | SCCO | |
|---|---|---|
Market Cap | $182.40B | $167.74B |
Volume | 4,469,821 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $219.70 |
52-Week Low | $116.74 | $120.02 |
Typical Hold Time | 111 Days | 61 Days |
Enterprise Value | $205.46B | $169.03B |
Dividend Yield | 2.23% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
SCCO trades at $200.57, down 1.81% on the day, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and impressive profitability margins including 35.87% net income margin. Recent earnings beats and a $10.2B Mexican project pipeline support growth prospects, though the stock trades at premium valuations with P/E of 30.1 and P/S of 10.82.
While SCCO's operational strength and copper demand from AI infrastructure provide upside potential, the stock faces headwinds from its premium valuation relative to peers and mixed analyst sentiment with only 10.34% buy ratings. The current price sits above the consensus target of $167.67, suggesting limited near-term upside despite strong cash flow generation and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
